tbuckley/cabot-search huggingface dataset:
Engineered Hollow Nanocomplex Combining Photothermal and Antioxidant Strategies for Targeted Tregs Depletion and Potent Immune Activation in Tumor Immunotherapy
Authors: Qi Sun, Yuyan Wang, Hetian Ren, Shiyuan Hou, Kaiyi Niu, Liu Wang, Siyu Liu, Jingyi Ye, Chunying Cui, Xianrong Qi
Journal: Advanced Healthcare Materials (2025)

Abstract In the tumor immunosuppressive microenvironment (TIME), regulatory T cells (Tregs) critically suppress anticancer immunity, characterized by high expression of glucocorticoid‐induced TNF receptor (GITR) expression and sensitivity to reactive oxygen species (ROS). This study develops a near‐infrared (NIR)‐responsive hollow nanocomplex (HPDA‐OPC/DTA‐1) using hollow polydopamine nanoparticles (HPDA), endowed with thermogenic and antioxidative properties, specifically targeting Tregs to activate antitumor immunity. The GITR agonist DTA‐1, combined with the antioxidant oligomeric proanthocyanidins (OPC) to deplete Tregs. However, Tregs depletion alone may not sufficiently trigger robust immune responses. The HPDA nanocarrier enhances thermogenic and antioxidative capacities, supporting photothermal immunotherapy. The HPDA‐OPC/DTA‐1 demonstrates NIR responsiveness for both photothermal therapy (PTT) and OPC release, while facilitating Tregs depletion via DTA‐1 and reducing ROS levels, thereby reviving antitumor immunity. Notably, intratumoral CD4 + CD25 + FOXP3 + Tregs exhibited a 4.08‐fold reduction alongside a 49.11‐fold increase in CD8 + T cells/Tregs relative to controls. Enhanced dendritic cells (DCs) maturation and immunogenic cell death (ICD) induction further demonstrate that HPDA‐OPC/DTA‐1 alleviates immunosuppression and activates antitumor immunity. Ultimately, the observed tumor inhibitory effect (tumor volume: 6.75‐fold versus the control) and an over 80% survival rate highlight the therapeutic potential of combining Tregs targeting, antioxidant strategy, and photothermal immunotherapy for effective cancer treatment.
European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Infertility
Authors: Suks Minhas, Luca Boeri, Paolo Capogrosso, Andrea Cocci, Giovanni Corona, Marij Dinkelman-Smit, Marco Falcone, Christian Fuglesang Jensen, Murat Gül, Arif Kalkanli, Ates Kadioğlu, Juan I Martinez-Salamanca, L Afonso Morgado, Giorgio I Russo, Ege Can Serefoğlu, Paolo Verze, Andrea Salonia
Journal: European Urology (2025)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Authors: Axel Bex, Yasmin Abu Ghanem, Laurence Albiges, Stephanie Bonn, Riccardo Campi, Umberto Capitanio, Saeed Dabestani, Milan Hora, Tobias Klatte, Teele Kuusk, Lars Lund, Lorenzo Marconi, Carlotta Palumbo, Geraldine Pignot, Thomas Powles, Natasha Schouten, Maxine Tran, Alessandro Volpe, Jens Bedke
Journal: European Urology (2025)
Functional Disability, Violence, HIV Status, and Risk Factors for HIV Among Adolescent Girls and Young Women — Eswatini, 2022
Authors: Ghenet Besera, Francis B. Annor, Elizabeth A. Swedo, Laura F. Chiang, Sana N. Charania, Phumzile Mndzebele, Michelle J. Li, Jennifer Hegle, Anne Laterra, Robyn A. Cree, Nozipho Nzuza-Motsa, Thobile Mkhonta, Kristopher Mills, Silke Felton, Greta M. Massetti
Journal: MMWR Morbidity and Mortality Weekly Report (2025)

Eswatini has made substantial progress responding to its HIV epidemic and reducing violence against children. However, adolescent girls and young women with disabilities might be at increased risk for experiencing violence and for HIV infection, compared with those without disabilities. Data from the 2022 Eswatini Violence Against Children and Youth Survey were analyzed to compare HIV infection and violence-related measures by functional disability status (e.g., difficulties in performing functional activities such as seeing, walking, or communicating) among adolescent girls and young women. In 2022, in Eswatini, 14.0% of adolescent girls and young women aged 13-24 years had a reported functional disability. Compared with those without a functional disability, adolescent girls and young women with a functional disability had higher lifetime prevalences of experiencing sexual, physical, and emotional violence. They were also more likely to know where to seek help for experiences of violence. After adjusting for sociodemographic characteristics, HIV testing and infection status, HIV risk factors, sexual risk behaviors, and HIV treatment and prevention services did not differ by functional disability status. Prioritizing accessible, disability-inclusive prevention programs and services might help reduce experiences of violence among adolescent girls and young women with disabilities. Partnering with disability-led and disability-serving organizations and directly with adolescent girls and young women with disabilities to plan and implement programs and services that are disability-inclusive could help ensure that adolescent girls and young women with disabilities are aware of and can access these resources.
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update
Authors: Alexandra Masson-Lecomte, Alison Birtle, Benjamin Pradere, Otakar Capoun, Eva Compérat, José L Domínguez-Escrig, Fredrik Liedberg, Lydia Makaroff, Paramananthan Mariappan, Marco Moschini, Bhavan P Rai, Bas W G van Rhijn, Shahrokh F Shariat, Emma J Smith, Jeremy Y C Teoh, Viktor Soukup, Robert Wood, Evanguelos N Xylinas, Francesco Soria, Thomas Seisen, Paolo Gontero
Journal: European Urology (2025)
European Association of Urology-European Society of Paediatric Urology Guidelines on Paediatric Urology: Summary of 2024 Updates. Part II
Authors: Martin Skott, Uchenna Kennedy, Michele Gnech, Allon van Uitert, Anna Bujons, Lisette 't Hoen, Yazan F Rawashdeh, Mesrur Selcuk Silay, Fardod O'Kelly, Josine Quaedackers, Niklas Pakkasjärvi, Yuhong Yuan, Berk Burgu, Marco Castagnetti, Guy Bogaert, Christian Radmayr
Journal: European Urology (2025)
Dermatitis cruris pustulosa et atrophicans
Authors: Javier de la Iglesia Martin, Jessica Martin Vera, Carla Tubau Prims
Journal: British Journal of Dermatology (2025)

A 40-year-old man from Malawi developed scaly plaques with alopecia after 3 years of pustular lesions, diagnosed as dermatitis cruris pustulosa et atrophicans (DCPA), a chronic folliculitis with no definitive treatment.
A Novel 3D High‐Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer
Authors: Nazanin Karimnia, Amy L. Wilson, Brittany R. Doran, Jennie Do, Amelia Matthews, Gwo Y. Ho, Magdalena Plebanski, Thomas W. Jobling, Andrew N. Stephens, Maree Bilandzic
Journal: Advanced Healthcare Materials (2025)

Abstract Ovarian cancer (OC) poses a significant clinical challenge due to its high recurrence rates and resistance to standard therapies, particularly in advanced stages where recurrence is common, and treatment is predominantly palliative. Personalized treatments, while effective in other cancers, remain underutilized in OC due to a lack of reliable biomarkers predicting clinical outcomes. Accordingly, precision medicine approaches are limited, with PARP inhibitors showing efficacy only in specific genetic contexts. Drug repurposing offers a promising, rapidly translatable strategy by leveraging existing pharmacological data to identify new treatments for OC. Patient‐derived polyclonal spheroids, isolated from ascites fluid closely mimic the clinical behavior of OC, providing a valuable model for drug testing. Using these spheroids, a high‐throughput drug screening pipeline capable of evaluating both cytotoxicity and anti‐migratory properties of a diverse drug library, including FDA‐approved, investigational, and newly approved compounds is developed. The findings highlight the importance of 3D culture systems, revealing a poor correlation between drug efficacy in traditional 2D models and more clinically relevant 3D spheroids. This approach has expedited the identification of promising candidates, such as rapamycin, which demonstrated limited activity as a monotherapy but synergized effectively with standard treatments like cisplatin and paclitaxel in vitro. In combination with platinum‐based therapy, Rapamycin led to significant in vitro cytotoxicity and a marked reduction in tumor burden in a syngeneic in vivo model. This proof‐of‐concept study underscores the potential of drug repurposing to rapidly advance new treatments into clinical trials for OC, offering renewed hope for patients with advanced disease.
Magnesium Hexacyanoferrate Mitigates Sepsis-Associated Encephalopathy through Inhibiting Microglial Activation and Neuronal Cuproptosis
Authors: Yabing Zhang, Juan Xin, Di Zhao, Gezi Chen, Penghao Ji, Panmiao Liu, Hua Wei, Hongwei Wang, Yuzhong Xia, Yong Wang, Zhongyu Wang, Xiangyi Ren, Minfeng Huo, Hai Yu, Jianjun Yang
Journal: Biomaterials (2025)
An Expandable Brain‐Machine Interface Enabled by Origami Materials and Structures for Tracking Epileptic Traveling Waves
Authors: Tiancheng Sheng, Jingwei Li, Lingyi Zheng, Nianzhen Du, Mingxiao Xie, Xiaolong Wang, Xize Gao, Mengsha Huang, Shenghan Wen, Wenqian Liu, Yong Guo, Yi Yao, Xiaoqiu Shao, Lianqing Liu, Jing Xu, Yilong Wang, Mingjun Zhang
Journal: Advanced Healthcare Materials (2025)

Abstract Tracking neural activities across multiple brain regions remains a daunting challenge due to the non‐negligible skull injuries during implantations of large‐area electrocorticography (ECoG) grids and the limited spatial accessibility of conventional rectilinear depth probes. Here, a multiregion Brain‐machine Interface (BMI) is proposed comprising an expandable bio‐inspired origami ECoG electrode covering cortical areas larger than the cranial window, and an expandable origami depth probe capable of reaching multiple deep brain regions beyond a single implantation axis. Using the proposed BMI, it is observed that, in rat models of focal seizures, cortical multiband epileptiform activities mainly manifest as expanding traveling waves outward from a cortical source.
Disparities in Current Pulmonary Embolism Management and Outcomes: A Scientific Statement From the American Heart Association
Authors: Edwin A. Takahashi, Akhilesh K. Sista, Daniel Addison, Behnood Bikdeli, Vivian L. Bishay, Sue Gu, Maureen N. Hood, Diana Litmanovich, Sanjay Misra, Gautham Reddy
Journal: Circulation (2025)

Pulmonary embolism is a common cause of cardiovascular-associated morbidity and mortality. Although pulmonary embolism affects individuals from all demographics, the incidence of pulmonary embolism is higher among people from certain racial groups, reproductive-age women compared with age-matched men, and transgender people taking estrogen hormones. Furthermore, disparities may exist in the diagnosis or management strategies of pulmonary embolism associated with race, ethnicity, sex, or socioeconomic status, which may correlate with poorer downstream outcomes, including recurrent pulmonary embolism, chronic thromboembolic pulmonary hypertension, or short- or long-term mortality. This scientific statement summarizes disparities in diagnosis, treatment strategies, and outcomes related to pulmonary embolism, and reviews approaches to create equitable pulmonary embolism care and address the knowledge gaps in the literature.
Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy
Authors: Ayeskanta Mohanty, Adityanarayan Mohapatra, Woojin Yang, Seunghyun Choi, Aravindkumar Sundaram, Yong‐Yeon Jeong, Chang‐Moon Lee, Jiwon Seo, In‐Kyu Park
Journal: Advanced Healthcare Materials (2025)

Abstract Despite the great potential of photodynamic therapy (PDT), its success remains compromised by the abnormal redox homeostasis of tumor cells, which supports survival, growth, and resistance to oxidative therapeutic interventions by neutralizing reactive oxygen species (ROS). To overcome this barrier, a multifunctional prodrug nanomodulator (Pro@FLNC) is designed to induce disulfidptosis and immunogenic pyroptosis to trigger an antitumor immune response. Pro@FLNC features a prodrug core–shell structure where ursolic acid (UA) and Chlorin e6 (Ce6) are conjugated via a GSH‐responsive linker and encapsulated in a DSPE‐PEG‐FA lipid shell for enhanced stability, biocompatibility, and tumor‐specific targeting. Within the tumor microenvironment (TME), Pro@FLNC depletes intracellular GSH, disrupts redox homeostasis, and releases Ce6 and UA, triggering oxidative stress and mitochondrial dysfunction. These mechanisms amplify ROS production, promote lipid peroxidation, and initiate disulfidptosis, evidenced by increased SLC7A11 expression and F‐actin collapse. Elevated ROS levels and metabolic imbalance‐triggered disulfidptosis further activate immunogenic pyroptosis, releasing damage‐associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and cytotoxic T‐cell activation. Together, Pro@FLNC reshapes the TME, reduces immunosuppressive cells, and promotes CD8 + T‐cell infiltration, effectively suppressing primary tumors and metastases. This programmed prodrug nanomodulator offers a promising strategy to enhance PDT and immunotherapy for advanced breast cancer.
Multifunctional Hydrogel Integrated Hemangioma Stem Cell‐Derived Nanovesicle‐Loaded Metal‐Polyphenol Network Promotes Diabetic Flap Survival
Authors: Rui Chang, Pei Wang, Hongrui Chen, Shih‐Jen Chang, Qianyi Chen, Lei Chang, Yajing Qiu, Xiansong Wang, Xiaoxi Lin
Journal: Advanced Healthcare Materials (2025)

Abstract Diabetes‐associated skin defects represent a significant global health challenge. While flap grafts have been a preferred treatment for soft‐tissue injuries in diabetic patients, their survival is often compromised by impaired vascularization, infection, and the adverse diabetic pathological microenvironment. To address these limitations, a hybrid photo‐crosslinkable hydrogel (HPC) integrated hemangioma stem cell‐derived nanovesicle (HemV)‐loaded dual‐metal‐polyphenol network (dMPN) (HemV@dMPN/HPC) is developed. HemVs, derived from highly vascularized infantile hemangioma tissues, play a key role in promoting cell proliferation and angiogenesis. The dMPN facilitates the gradual release of copper (Cu 2+ ) and magnesium ions (Mg 2+ ), stimulating angiogenesis and mitigating inflammation. The HPC further sustains ion release while preserving the therapeutic efficacy of HemVs. Moreover, both HPC and Cu 2+ act to confer antibacterial properties, further accelerating wound healing. This multifunctional HemV@dMPN/HPC platform offers a promising therapeutic strategy for treating large diabetic skin defects and can potentially improve flap graft survival.
Exosomes derived from MSCs exposed to hypoxic and inflammatory environments slow intervertebral disc degeneration by alleviating the senescence of nucleus pulposus cells through epigenetic modifications
Authors: Yongzhao Zhao, Longting Chen, Shuai Jiang, Zhenquan Wu, Qian Xiang, Jialiang Lin, Shuo Tian, Zhuoran Sun, Chuiguo Sun, Weishi Li
Journal: Bioactive Materials (2025)
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non–small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy
Authors: You Cheng, Zhen-peng Jiang, Xiao-bo Chen, Kai-yu Lu, Zai-yi Liu, Dan Shao
Journal: Clinical Nuclear Medicine (2025)

Objective: This study investigates the predictive value of 18 F-FDG PET/CT metabolic parameters in patients with non–small cell lung cancer (NSCLC) undergoing neoadjuvant immunotherapy plus chemotherapy. Methods: We conducted a retrospective analysis of clinical data from 131 patients with pathologically confirmed NSCLC who were deemed resectable after 3 cycles of neoadjuvant immunotherapy plus chemotherapy. Pretreatment and post-treatment PET metabolic parameters were evaluated. CT assessments based on immune response evaluation criteria in solid tumors (iRECIST) were compared with PET/CT assessments using the response criteria in solid tumors (PERCIST). ROC curve analysis and Kaplan-Meier survival analysis, including univariate and Cox multivariate analyses, were employed to assess the prognostic value of PET metabolic parameters after treatment. Results: The PET/CT assessment based on PERCIST showed high consistency with prognosis, while the CT assessment based on iRECIST demonstrated low consistency. Statistically significant differences were observed between the iRECIST and PERCIST criteria ( P &lt;0.001). ROC curve analysis revealed significant differences in post-treatment PET metabolic parameters (postSUVmax, postSUVmean, postSUVpeak, postMTV, and postTLG) as well as the percentage changes in metabolic parameters before and after treatment(Δ) (ΔSUVmax, ΔSUVmean, ΔSUVpeak, ΔMTV, and ΔTLG) ( P &lt;0.05). Optimal cutoff values enabled stratification into high-risk and low-risk groups. Univariate analysis showed significantly higher survival in the low-risk group for all parameters except ΔMTV ( P =0.311), while Cox multivariate analysis identified ΔSUVmax as the most predictive. Conclusions: The PERCIST is more accurate than iRECIST in evaluating prognosis for NSCLC neoadjuvant immunotherapy plus chemotherapy. PET metabolic parameters, particularly ΔSUVmax, effectively predict prognosis and support clinical decision-making.
Hospitalisations for physical abuse in infants and children less than 5 years, 2013–2021: a multinational cohort study using administrative data from five European countries
Authors: Catherine Quantin, Jonathan Cottenet, Colleen Chambers, Natasha Kennedy, Sadhbh Whelan, Geoff Debelle, Diogo Lamela, Ulugbek Nurmatov, Donna O'Leary, Christian Torp-Pedersen, Sinéad Brophy, Marcella Broccia, Ruth Gilbert, Troels Græsholt-Knudsen, Laura Elizabeth Cowley
Journal: The Lancet Regional Health - Europe (2025)
Correction: Sorafenib enhanced the function of myeloid‑derived suppressor cells in hepatocellular carcinoma by facilitating PPARα‑mediated fatty acid oxidation
Authors: Chunxiao Li, Liting Xiong, Yuhan Yang, Ping Jiang, Junjie Wang, Mengyuan Li, Shuhua Wei, Suqing Tian, Yuexuan Wang, Mi Zhang, Jie Tang
Journal: Molecular Cancer (2025)
3D tumor cultures for drug resistance and screening development in clinical applications
Authors: Zheng Peng, Xiaolan Lv, Hao Sun, Lina Zhao, Shigao Huang
Journal: Molecular Cancer (2025)

Tumor drug resistance presents a growing challenge in medical practice, particularly during anti-cancer therapies, where the emergence of drug-resistant cancer cells significantly complicates clinical treatment. In recent years, three-dimensional (3D) tumor culture technology, which more effectively simulates the in vivo physiological environment, has gained increasing attention in tumor drug resistance research and clinical applications. By mimicking the in vivo cellular microenvironment, 3D tumor culture technology not only recapitulates cell-cell interactions but also more faithfully reproduces the biological effects of therapeutic agents. Consequently, 3D tumor culture technology is emerging as a crucial tool in biomedical and clinical research. We summarize the benefits of 3D culture models and organoid technology, explore their application in the realm of drug resistance, drug screening, and personalized therapy, and discuss their potential application prospects and challenges in clinical transformation, with the aim of providing insights for optimizing cancer treatment strategies and advancing precision therapy.
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin
Authors: Zehao Wang, Lu Yang, Peng Wu, Xing Li, Yuhui Tang, Xueqi Ou, Yue Zhang, Xiangsheng Xiao, Jin Wang, Hailin Tang
Journal: Molecular Cancer (2025)
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment
Authors: Pu Zhang, Ethan C. Whipp, Sarah J. Skuli, Mehdi Gharghabi, Caner Saygin, Steven A. Sher, Martin Carroll, Xiangyu Pan, Eric D. Eisenmann, Tzung-Huei Lai, Bonnie K. Harrington, Wing Keung Chan, Youssef Youssef, Bingyi Chen, Alex Penson, Alexander M. Lewis, Cynthia R. Castro, Nina Fox, Ali Cihan, Jean-Benoit Le Luduec, Susan DeWolf, Tierney Kauffman, Alice S. Mims, Daniel Canfield, Hannah Phillips, Katie E. Williams, Jami Shaffer, Arletta Lozanski, Tzyy-Jye Doong, Gerard Lozanski, Charlene Mao, Christopher J. Walker, James S. Blachly, Anthony F. Daniyan, Lapo Alinari, Robert A. Baiocchi, Yiping Yang, Nicole R. Grieselhuber, Moray J. Campbell, Sharyn D. Baker, Bradley W. Blaser, Omar Abdel-Wahab, Rosa Lapalombella
Journal: Journal of Clinical Investigation (2025)

Mutations and deletions in TP53 are associated with adverse outcomes in patients with myeloid malignancies and developing improved therapies for TP53-mutant leukemias is of urgent need. Here we identify mutations in TET2 as the most common co-occurring mutation in TP53 mutant acute myeloid leukemia (AML) patients. In mice, combined hematopoietic-specific deletion of TET2 and TP53 resulted in enhanced self-renewal compared to deletion of either gene alone. Tp53/Tet2 double knockout mice developed serially transplantable AML. Both mice and AML patients with combined TET2/TP53 alterations upregulated innate immune signaling in malignant granulocyte-monocyte progenitors (GMPs), which had leukemia-initiating capacity. A20 governs the leukemic maintenance by triggering aberrant non-canonical NF-κB signaling. Mice with Tp53/Tet2 loss had expansion of monocytic myeloid-derived suppressor cells (MDSCs), which impaired T cell proliferation and activation. Moreover, mice and AML patients with combined TP53/TET2 alterations displayed increased expression of the TIGIT ligand, CD155, on malignant cells. TIGIT blocking antibodies augmented NK cell-mediated killing of Tp53/Tet2 double-mutant AML cells, reduced leukemic burden, and prolonged survival in Tp53/Tet2 double knockout mice. These findings uncover a leukemia-promoting link between TET2 and TP53 mutations and highlight therapeutic strategies to overcome the immunosuppressive bone marrow environment in this adverse subtype of AML.
Acoustic inspired brain-to-sentence decoder for logosyllabic language
Authors: Chen Feng, Lu Cao, Di Wu, En Zhang, Ting Wang, Xiaowei Jiang, Jinbo Chen, Hui Wu, Siyu Lin, Qiming Hou, Junming Zhu, Jie Yang, Mohamad Sawan, Yue Zhang
Journal: Cyborg and Bionic Systems (2025)

Recent advances in brain–computer interfaces (BCIs) have demonstrated the potential to decode language from brain activity into sound or text, which has predominantly focused on alphabetic languages, such as English. However, logosyllabic languages, such as Mandarin Chinese, present marked challenges for establishing decoders that cover all characters, due to its unique syllable structures, extended character sets (e.g., over 50,000 characters for Mandarin Chinese), and complex mappings between characters and syllables, thus hindering practical applications. Here, we leverage the acoustic features of Mandarin Chinese syllables, constructing prediction models for syllable components (initials, tones, and finals), and decode speech-related stereoelectroencephalography (sEEG) signals into coherent Chinese sentences. The results demonstrate a high sentence-level offline decoding performance with a median character accuracy of 71.00% over the full spectrum of characters in the best participant. We also verified that incorporating acoustic-related features into the design of prediction models substantially enhances the accuracy of initials, tones, and finals. Moreover, our findings revealed that effective speech decoding also involves subcortical structures like the thalamus in addition to traditional language-related brain regions. Overall, we established a brain-to-sentence decoder for logosyllabic languages over full character set with a large intracranial electroencephalography dataset.
Remote limb ischemic conditioning alleviates steatohepatitis via extracellular vesicle-mediated muscle-liver crosstalk
Authors: Yichao Zhao, Ling Gao, Jianqing Chen, Jingze Wei, Guanqiao Lin, Kewei Hu, Wubin Zhao, Weijun Wei, Wei Huang, Lingchen Gao, Ancai Yuan, Kun Qian, Alex F Chen, Jun Pu
Journal: Cell Metabolism (2025)